New automations receive FDA clearance for use in coronary and peripheral robotic-assisted procedures
WALTHAM, Mass., — December 15, 2020 — Corindus, A Siemens Healthineers Company and one of the leading developers of precision vascular robotics, announced today the global launch of a new set of automated robotic movements in the technIQ Series designed for the CorPath GRX System. The company received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for new software automation that provides predictable and consistent movements to aid in advanced device manipulation during complex coronary and peripheral procedures.
Jean Fajadet, M.D., the co-director of interventional cardiology at Clinique Pasteur in Toulouse, France, performed the first in-human coronary procedures with the benefit of the new automated movements, which replicate manual techniques of highly skilled interventionalists. The procedures demonstrated how the new movements can help to reduce procedure time associated with wire and device manipulation and drive standardization in quality of care by offering advanced techniques to all physicians.
“This new software algorithm gives the operator new possibilities to advance and facilitate treatment, especially with complex lesions,” said Dr. Fajadet. “I am pleased with the success of using the automated moves and am honored to play a role in the advancement of robotic technology that will make interventional procedures more efficient and safer for our patients.”
In 2018, Corindus received CE Mark and FDA clearance for an automated technique called Rotate on Retract (RoR). RoR was the first automated robotic movement in the technIQ Series and has demonstrated the potential to significantly reduce wiring time. The latest global introduction and FDA clearance for the technIQ Series provides physicians with four additional automated robotic movements that aid with complex tasks such as crossing lesions, navigating tortuosity, and precisely measuring the anatomy for appropriate device size selection.
“The new technIQ movements mark the next phase in the evolution of robotic-assisted intervention and a vital step toward the advancement of our technology,” said Wayne Markowitz, Executive Vice President and Head of Corindus. “Automating more movements used in cardiovascular intervention will allow physicians to focus their attention on overall case strategy while equipping them with advanced techniques for navigating the vasculature.”
To learn more about Corindus and CorPath GRX, please visit www.corindus.com.
1. The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.
Corindus, a Siemens Healthineers company, is a global technology leader in robotic-assisted vascular interventions. The Company’s CorPath® platform is a medical device to bring robotic precision to percutaneous coronary and vascular procedures. CorPath GRX is the second-generation robotic-assisted technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. We are focused on developing innovative robotic solutions to revolutionize treatment of emergent conditions by providing specialized and timely medical care to patients around the world. For additional information, visit www.corindus.com, and follow @CorindusInc.
For more information, contact: